Niagen Bioscience Inc (NASDAQ:NAGE - Get Free Report)'s share price hit a new 52-week high during mid-day trading on Thursday . The company traded as high as $11.16 and last traded at $10.92, with a volume of 336528 shares. The stock had previously closed at $10.98.
Analyst Ratings Changes
Separately, Canaccord Genuity Group started coverage on shares of Niagen Bioscience in a report on Tuesday, May 27th. They set a "buy" rating and a $13.00 price target for the company.
Read Our Latest Stock Analysis on NAGE
Niagen Bioscience Price Performance
The firm has a market capitalization of $923.97 million, a price-to-earnings ratio of 69.00 and a beta of 1.94. The firm's fifty day moving average is $8.13.
About Niagen Bioscience
(
Get Free Report)
Niagen Bioscience, Inc is a global bioscience company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. It is pioneering research on nicotinamide adenine dinucleotide (NAD+). The company's patent portfolio includes Nicotinamide Riboside (NR) and other NAD+ precursors, which are commercialized as the flagship ingredient Niagen.
Featured Stories
Before you consider Niagen Bioscience, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Niagen Bioscience wasn't on the list.
While Niagen Bioscience currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
